CareDx Inc (CDNA)vsIQVIA Holdings Inc (IQV)
CDNA
CareDx Inc
$47.31
+0.17%
HEALTHCARE · Cap: $2.35B
IQV
IQVIA Holdings Inc
$241.71
-0.87%
HEALTHCARE · Cap: $38.68B
Smart Verdict
WallStSmart Research — data-driven comparison
IQVIA Holdings Inc generates 3607% more annual revenue ($16.98B vs $458.09M). CDNA leads profitability with a 24.2% profit margin vs 8.1%. CDNA trades at a lower P/E of 22.6x. IQV earns a higher WallStSmart Score of 55/100 (C).
CDNA
Buy53
out of 100
Grade: C-
IQV
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.3%
Fair Value
$62.15
Current Price
$47.31
$14.84 discount
Margin of Safety
+11.9%
Fair Value
$201.09
Current Price
$241.71
$40.62 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 52.2% year-over-year
Conservative balance sheet, low leverage
Keeps 24 of every $100 in revenue as profit
Every $100 of equity generates 22 in profit
Growing faster than its price suggests
Areas to Watch
0.0% earnings growth
Operating margin of 0.2%
ROE of -2.6% — below average capital efficiency
Distress zone — elevated risk
Moderate valuation
Weak financial health signals
Earnings declined 0.6%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : CDNA
The strongest argument for CDNA centers on Revenue Growth, Debt/Equity, Profit Margin. Profitability is solid with margins at 24.2% and operating margin at 0.2%. Revenue growth of 52.2% demonstrates continued momentum.
Bull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio. PEG of 0.98 suggests the stock is reasonably priced for its growth.
Bear Case : CDNA
The primary concerns for CDNA are EPS Growth, Operating Margin, Return on Equity.
Bear Case : IQV
The primary concerns for IQV are P/E Ratio, Piotroski F-Score, EPS Growth. Debt-to-equity of 2.63 is elevated, increasing financial risk.
Key Dynamics to Monitor
CDNA profiles as a growth stock while IQV is a value play — different risk/reward profiles.
CDNA carries more volatility with a beta of 2.42 — expect wider price swings.
CDNA is growing revenue faster at 52.2% — sustainability is the question.
IQV generates stronger free cash flow (360M), providing more financial flexibility.
Bottom Line
IQV scores higher overall (55/100 vs 53/100). CDNA offers better value entry with a 68.3% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CareDx Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.
IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?